'The publication of this data coupled with the recently expanded labeling provides clinicians the opportunity to evolve how we care for patients with uncontrolled gout,' said
The co-administration of KRYSTEXXA with an immunomodulator like methotrexate has increasingly been employed for patients with uncontrolled gout (chronic gout refractory to oral therapies) to help reduce the development of anti-drug antibodies, which can affect treatment efficacy.1,2 Following a series of case studies and an open-label study, the MIRROR randomized controlled trial (Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA trial, NCT03994731) was conducted3-5 and evaluated differences in treatment response for KRYSTEXXA with methotrexate compared to KRYSTEXXA with placebo.
The primary endpoint was the proportion of serum uric acid (sUA) responders defined as sUA
(C) 2022 Electronic News Publishing, source